Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06646757 · ClinicalTrials.gov registry record · NA
Exploring Multiple Self-Help Interventions to Promote Self-Efficacy and Overcome Disability
A NA study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 803
- Enrollment target
NCT06646757: Completed NA study, sponsored by University of Pennsylvania.
NCT06646757 is a NA study that has completed, run by University of Pennsylvania. The registered enrollment target is 803 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06646757, a NA study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 803 participants
- Enrollment target
Study Summary
EMPOWER-IBD aims to identify behavioral interventions to strengthen patients' self-efficacy for self-management as a mechanism to reduce IBD-related disability. This multisite, randomized controlled trial with 16 arms will randomize adults with moderate-to-severe IBD-related disability to a combination of four multimodal behavioral interventions to test their clinical effectiveness in reducing IBD-related disability and improving self-efficacy. The interventions are four existing, publicly available disease-specific self-help resources offered at no cost to the participants: a book, smart app, help center, and peer mentor. Participants will complete online surveys and may engage in virtual focus groups. Participants may receive an honorarium (e-gift card) and/or be entered into a lottery for a giftcards post-survey completion and focus group participation.
Primary Outcome
The study seeks to identify any changes in IBD-related disability pre-post intervention (week 0 and week 12) as measured by the IBD Disability Index (IBD-DI). IBD-related disability is measured by the validated 14-item IBD-disability index (yes-no responses and 1-5 point Likert scales) for limitations across 5 domains of International Classification of Functioning, Health, and Disability. Higher score indicates more disability. Total score ranges from 0-100, interpreted as 0-20 (no disability),
Interventions
- BEHAVIORAL CBT
- BEHAVIORAL HELP
- BEHAVIORAL APP
- BEHAVIORAL PEER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 803 participants |
| Start Date | 2024-08-14 |
| Est. Completion | 2025-10-15 |
| Phase | NA |
What the finished NCT06646757 record still lists
NCT06646757 is an interventional study that assigns participants to a tested intervention. The registered 803 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 4 interventions - of which CBT is the first listed.
NCT06646757 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06646757 about?
NCT06646757 is a clinical study titled "Exploring Multiple Self-Help Interventions to Promote Self-Efficacy and Overcome Disability". EMPOWER-IBD aims to identify behavioral interventions to strengthen patients' self-efficacy for self-management as a mechanism to reduce IBD-related disability. This multisite, randomized controlled trial with 16 arms will randomize adults with moderate-to-severe IBD-related disability to a combinat...
What is the current status of trial NCT06646757?
This trial is currently completed. It is a NA study. The enrollment target is 803 participants. The study started on 2024-08-14. Estimated completion is 2025-10-15.
What interventions are being tested in trial NCT06646757?
The interventions under investigation include: CBT (BEHAVIORAL), HELP (BEHAVIORAL), APP (BEHAVIORAL), PEER (BEHAVIORAL).
Who is sponsoring clinical trial NCT06646757?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06646757's enrollment target sits among peer trials
803 134th of 2000 higher than 1,867 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04423211 · 804 participants · Phase 3
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- NCT06522022 · 804 participants · NA
PTSD Screening in Pregnant Black Women
- NCT03524430 · 801 participants · NA
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI